GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Can B Corp (OTCPK:CANB) » Definitions » 1-Year ROIIC %

Can B (CANB) 1-Year ROIIC % : -37.58% (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Can B 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Can B's 1-Year ROIIC % for the quarter that ended in Sep. 2024 was -37.58%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Can B's 1-Year ROIIC % or its related term are showing as below:

CANB's 1-Year ROIIC % is ranked worse than
72.88% of 859 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs CANB: -37.58

Can B 1-Year ROIIC % Historical Data

The historical data trend for Can B's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can B 1-Year ROIIC % Chart

Can B Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.25 43.59 -21.63 -1,592.98 -328.79

Can B Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -396.25 -328.79 -58.26 -68.87 -37.58

Competitive Comparison of Can B's 1-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Can B's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can B's 1-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Can B's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Can B's 1-Year ROIIC % falls into.



Can B 1-Year ROIIC % Calculation

Can B's 1-Year ROIIC % for the quarter that ended in Sep. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -7.564 (Sep. 2024) - -9.4341 (Sep. 2023) )/( 9.275 (Sep. 2024) - 14.251 (Sep. 2023) )
=1.8701/-4.976
=-37.58%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Can B  (OTCPK:CANB) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Can B 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Can B's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Can B Business Description

Traded in Other Exchanges
N/A
Address
960 South Broadway, Suite 120, Hicksville, NY, USA, 11801
Can B Corp is engaged in the business of promoting health and wellness through its development, manufacture and sale of products containing cannabinoids derived from hemp biomass and the licensing of durable medical devices. The company focuses on developing a line of proprietary products in the Hemp Industry.
Executives
Mckenzie Webster Ltd 10 percent owner DMS HOUSE, DR. ROYCE DRIVE, GEORGE TOWN, GRAND CAYMAN E9 KY1-1102
Stanley L Teeple director, officer: CFO, Director, and Secretary 94 ARTHUR HILL COURT, HENDERSON NV 89014
Andrew Holtmeyer officer: EVP Business Development 65 LAUREN AVE, SUITE 301, HUNTINGTON STATION NY 11746
Heggenhougen Rolv director 90 NORTH CHURCH STREET, GEORGETOWN E9 KY1-1102
David J Posel officer: COO 6103 CARMEL LN SE, LACEY WA 98503
Rolv Heggenhougen 10 percent owner 445 NE 12TH AVENUE, FORT LAUDERDALE FL 33301
Marco Alfonsi director, 10 percent owner, officer: CEO, Board Member 44 EAST END AVENUE, HICKSVILLE NY 11801
Carl Dilley director 15500 ROOSEVELT BLVD., SUITE 301, CLEARWATER FL 33760

Can B Headlines

From GuruFocus

Can B Corp At Emerging Growth Conference Transcript

By GuruFocus Research 02-13-2024